Medical Management of Peyronie’s Disease: a 2014 Update

Peyronie’s disease (PD) is a connective tissue disorder characterized by the development of dense fibrous collagen plaque deposits in the tunica albuginea of the penis, resulting in curvature of the erection and sexual dysfunction. It is both a physically and psychologically devastating disorder that remains a considerable therapeutic dilemma due to incomplete characterization of its pathophysiology and the paucity of randomized controlled trials. Along with an underlying genetic predisposition, numerous studies have implicated pro-inflammatory cascades and oxidative stress in the development of PD. Medical therapies targeting these pathways can be partially effective at decreasing or inhibiting plaque formation and symptoms of PD. Such therapies include the broad categories of oral medication and vitamin supplements, intralesional injections, and penile traction. The recent FDA approval for intralesional collagenase clostridium histolyticum provides a significant advancement in the medical treatment of PD. In addition to highlighting the latest data supporting intralesional collagenase clostridium histolyticum, this update aims to review the most current literature on all of the available options for medical treatment of PD and to provide a practical approach to the clinical management of PD in the office setting.

Duke Scholars

Author Aaron Claude Lentz Urology